News
Phase 3 LIGHTHOUSE Study of LRRK2 Inhibitor BIIB122 Initiated in Parkinson Disease
October 12th 2022Similar to the recently commenced phase 2b LUMA study, BIIB122, an investigational small molecule inhibitor of LRRK2, will be evaluated in a cohort of 400 individuals with genetically mutated Parkinson disease.
AMX0035’s Safety as a Treatment for Patients with ALS: Lawrence Steinman, MD
October 12th 2022The Zimmermann Professor of Neurology and Neurological Sciences and Pediatrics at Stanford University discusses the biggest takeaway from the FDA approval of Amylyx’s therapy, marketed as Relyvrio, and the availability of the treatment for patients with ALS. [WATCH TIME: 5 minutes]
NeuroVoices: Wayne Feng, MD, FAHA, on Changing the Approach to Poststroke Neuromuscular Symptoms
October 12th 2022The division chief of stroke and vascular neurology at Duke Health discussed how clinicians have typically treated poststroke motor symptoms and how technology is expanding these capabilities.
Longer Periods Between Natalizumab Dosing Might Result in Increased T2 Lesion Count
October 11th 2022New data from the NOVA trial showed differences in the number of T2 lesions in patients with relapsing-remitting multiple sclerosis at 72 weeks of treatment with natalizumab (Tysabri; Biogen), though seemingly driven by data from only 2 participants with extreme new or newly enlarging T2 hyperintense lesion numbers.
Temporal Trends Show Increased Use of Antiseizure Medications With Lower Teratogenic Risk
October 11th 2022Valproic acid, which had been associated with a variety of major and minor malformations in pregnancy, remained barely unchanged in terms of use, dropping slightly from 12.4% to 10.1% over the 5-year period.
Approval of AMX0035 and the Future of Clinical Trials for ALS: Lawrence Steinman, MD
October 11th 2022The Zimmermann Professor of Neurology and Neurological Sciences and Pediatrics at Stanford University discussed updates in ALS research along with the need in future studies following AMX005’s (Relyvrio; Amylyx Pharmaceuticals) recent FDA approval. [WATCH TIME: 4 minutes]
Understanding the Complexity and Heterogenicity of Alzheimer Disease: Thomas Wisniewski, MD
October 11th 2022The director of NYU Langone’s Alzheimer’s Disease Research Center and Center for Cognitive Neurology discussed current knowns and unknowns about the pathology of Alzheimer disease. [WATCH TIME: 4 minutes]
Putting Pen to Paper: Executing on Approaches for Neurorestoration
October 11th 2022Joe Kardine, MS, OTR, CBIS, the clinical program manager at the Jefferson Center for Neurorestoration, discussed the influx of new neurorestorative technology and the future of treating patients with functional loss.
Approach to Poststroke Neuromuscular and Motor Symptoms: Wayne Feng, MD, FAHA
October 10th 2022The division chief of stroke and vascular neurology at Duke Health provided insight on the nuances of poststroke neuromuscular symptoms and how they differ from other typically managed impairments. [WATCH TIME: 5 minutes]
Day-of-injury Plasma GFAP and UCH-L1 Predict Functional Recovery After Traumatic Brain Injury
October 10th 2022The TRACK-TBI cohort study revealed that patients with traumatic brain injury and a GCS score of 3 to 12 had a significant increase in the accuracy of prognostic accuracy of IMPACT models.
Breakthrough in ALS With FDA Approval of AMX0035: Lawrence Steinman, MD
October 10th 2022The Zimmermann Professor of Neurology and Neurological Sciences and Pediatrics at Stanford University discusses Amylyx’s therapy that was recently approved by the FDA, and what it means for the ALS community and the global healthcare industry. [WATCH TIME: 5 minutes]
Supernus Issued CRL for Continuous Apomorphine Infusion in Parkinson Disease
October 10th 2022The NDA for the Supernus therapy, supported by data from the phase 3 TOLEDO study in patients with Parkinson disease, will require additional information and 6 months of further review. No additional efficacy or safety studies are required.
Combination of Biomarkers Associated with Stronger Predictions of Progression in Parkinson Disease
October 8th 2022Findings from a study on Parkinson disease revealed that combining blood biomarkers in addition with clinical measures with prognostics modelling are associated with a more vital prediction in disease progression.
Total N-Acetylaspartate Different Across Antibody-Negative Overlapping Multiple Sclerosis, NMOSD
October 8th 2022Using magnetic resonance spectroscopy, investigators observed significantly different levels of total NAA across MS and NMOSD subtypes, and a negative correlation between total NAA and disability score.
Phase 3 Findings Highlight Hydromethylthionine Mesylate’s Potential as Alzheimer Treatment
October 7th 2022When hydromethylthionine mesylate was compared with publicly available placebo decline data, the treatment effects of cognitive and functional decline are about 3-fold larger over 18 months.
Unique Aspects of Caring for Women With Multiple Sclerosis: Riley Bove, MD
October 7th 2022The neurologist at the University of California, San Francisco offered an overview of the State of the Science Summit that was held on September 28, 2022, featuring a panel of expert clinicians. [WATCH TIME: 7 minutes]
AUPN 2022 Veterans Health Administration Workshop
Glenn Graham, MD, PhD; and Sharyl Martini, MD, PhD, moderate a discussion with 4 clincial experts to advance specialized clinical care, education and research for Veterans with movement disorders, multiple sclerosis, epilepsy and seizures, and headache. [WATCH TIME: 1 hour, 52 minutes]
NeurologyLive® Top Expert Interviews: September 2022
October 6th 2022Expert clinicians offer their perspectives on developmental milestones for children, the NMSOD patient perspective, effective treatments for insomnia, ALS, diabetic and inflammatory neuropathies, and lecanemab in early Alzheimer disease.
